OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.23 USD
0.00 (0.00%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $1.24 +0.01 (0.81%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.23 USD
0.00 (0.00%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $1.24 +0.01 (0.81%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -1.25% move from the prior day.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
by Zacks Equity Research
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.04 in the latest trading session, marking a -0.65% move from the prior day.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $2.87 in the latest trading session, marking a -1.37% move from the prior day.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment
by Zacks Equity Research
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients
by Zacks Equity Research
Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.
OPKO Health (OPK) Receives FDA Nod for the 4Kscore Test
by Zacks Equity Research
OPKO Health (OPK) gets FDA nod for its 4Kscore Test that will further validate its value of being an important tool in the diagnosis of prostate cancer.
OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.
OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.
OPKO Health (OPK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 500.00% and 26.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed
by Zacks Equity Research
The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?